Chris Sampson’s journal round-up for 11th March 2019

Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.

Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force report. Value in Health [PubMed] Published 1st March 2019

When modellers select health state utility values to plug into their models, they often do it in an ad hoc and unsystematic way. This ISPOR Task Force report seeks to address that.

The authors discuss the process of searching, reviewing, and synthesising utility values. Searches need to use iterative techniques because evidence requirements develop as a model develops. Due to the scope of models, it may be necessary to develop multiple search strategies (for example, for different aspects of disease pathways). Searches needn’t be exhaustive, but they should be systematic and transparent. The authors provide a list of factors that should be considered in defining search criteria. In reviewing utility values, both quality and appropriateness should be considered. Quality is indicated by the precision of the evidence, the response rate, and missing data. Appropriateness relates to the extent to which the evidence being reviewed conforms to the context of the model in which it is to be used. This includes factors such as the characteristics of the study population, the measure used, value sets used, and the timing of data collection. When it comes to synthesis, the authors suggest it might not be meaningful in most cases, because of variation in methods. We can’t pool values if they aren’t (at least roughly) equivalent. Therefore, one approach is to employ strict inclusion criteria (e.g only EQ-5D, only a particular value set), but this isn’t likely to leave you with much. Meta-regression can be used to analyse more dissimilar utility values and provide insight into the impact of methodological differences. But the extent to which this can provide pooled values for a model is questionable, and the authors concede that more research is needed.

This paper can inform that future research. Not least in its attempt to specify minimum reporting standards. We have another checklist, with another acronym (SpRUCE). The idea isn’t so much that this will guide publications of systematic reviews of utility values, but rather that modellers (and model reviewers) can use it to assess whether the selection of utility values was adequate. The authors then go on to offer methodological recommendations for using utility values in cost-effectiveness models, considering issues such as modelling technique, comorbidities, adverse events, and sensitivity analysis. It’s early days, so the recommendations in this report ought to be changed as methods develop. Still, it’s a first step away from the ad hoc selection of utility values that (no doubt) drives the results of many cost-effectiveness models.

Estimating the marginal cost of a life year in Sweden’s public healthcare sector. The European Journal of Health Economics [PubMed] Published 22nd February 2019

It’s only recently that health economists have gained access to data that enables the estimation of the opportunity cost of health care expenditure on a national level; what is sometimes referred to as a supply-side threshold. We’ve seen studies in the UK, Spain, Australia, and here we have one from Sweden.

The authors use data on health care expenditure at the national (1970-2016) and regional (2003-2016) level, alongside estimates of remaining life expectancy by age and gender (1970-2016). First, they try a time series analysis, testing the nature of causality. Finding an apparently causal relationship between longevity and expenditure, the authors don’t take it any further. Instead, the results are based on a panel data analysis, employing similar methods to estimates generated in other countries. The authors propose a conceptual model to support their analysis, which distinguishes it from other studies. In particular, the authors assert that the majority of the impact of expenditure on mortality operates through morbidity, which changes how the model should be specified. The number of newly graduated nurses is used as an instrument indicative of a supply-shift at the national rather than regional level. The models control for socioeconomic and demographic factors and morbidity not amenable to health care.

The authors estimate the marginal cost of a life year by dividing health care expenditure by the expenditure elasticity of life expectancy, finding an opportunity cost of €38,812 (with a massive 95% confidence interval). Using Swedish population norms for utility values, this would translate into around €45,000/QALY.

The analysis is considered and makes plain the difficulty of estimating the marginal productivity of health care expenditure. It looks like a nail in the coffin for the idea of estimating opportunity costs using time series. For now, at least, estimates of opportunity cost will be based on variation according to geography, rather than time. In their excellent discussion, the authors are candid about the limitations of their model. Their instrument wasn’t perfect and it looks like there may have been important confounding variables that they couldn’t control for.

Frequentist and Bayesian meta‐regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data. Health Economics [PubMed] Published 20th February 2019

The first paper in this round-up was about improving practice in the systematic review of health state utility values, and it indicated the need for more research on the synthesis of values. Here, we have some. In this study, the authors conduct a meta-analysis of utility values alongside an analysis of registry and clinical study data for multiple myeloma patients.

A literature search identified 13 ‘methodologically appropriate’ papers, providing 27 health state utility values. The EMMOS registry included data for 2,445 patients in 22 counties and the APEX clinical study included 669 patients, all with EQ-5D-3L data. The authors implement both a frequentist meta-regression and a Bayesian model. In both cases, the models were run including all values and then with a limited set of only EQ-5D values. These models predicted utility values based on the number of treatment classes received and the rate of stem cell transplant in the sample. The priors used in the Bayesian model were based on studies that reported general utility values for the presence of disease (rather than according to treatment).

The frequentist models showed that utility was low at diagnosis, higher at first treatment, and lower at each subsequent treatment. Stem cell transplant had a positive impact on utility values independent of the number of previous treatments. The results of the Bayesian analysis were very similar, which the authors suggest is due to weak priors. An additional Bayesian model was run with preferred data but vague priors, to assess the sensitivity of the model to the priors. At later stages of disease (for which data were more sparse), there was greater uncertainty. The authors provide predicted values from each of the five models, according to the number of treatment classes received. The models provide slightly different results, except in the case of newly diagnosed patients (where the difference was 0.001). For example, the ‘EQ-5D only’ frequentist model gave a value of 0.659 for one treatment, while the Bayesian model gave a value of 0.620.

I’m not sure that the study satisfies the recommendations outlined in the ISPOR Task Force report described above (though that would be an unfair challenge, given the timing of publication). We’re told very little about the nature of the studies that are included, so it’s difficult to judge whether they should have been combined in this way. However, the authors state that they have made their data extraction and source code available online, which means I could check that out (though, having had a look, I can’t find the material that the authors refer to, reinforcing my hatred for the shambolic ‘supplementary material’ ecosystem). The main purpose of this paper is to progress the methods used to synthesise health state utility values, and it does that well. Predictably, the future is Bayesian.



  • punk rock health economist ORCID: 0000-0001-9470-2369

This site uses Akismet to reduce spam. Learn how your comment data is processed.